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Abstract 
Background: Periodontitis is an infectious disease that manifests as alveolar bone loss surrounding the roots of 
teeth. Diabetes aggravates periodontitis‑induced alveolar bone loss via suppression of bone formation. Intermittent 
parathyroid hormone (PTH) administration displays an anabolic effect on bone. In this study, we investigated the 
effect of intermittent PTH administration on alveolar bone loss in type 1 diabetic rats with periodontitis.
Methods: Rats were divided into control (C), periodontitis (P), periodontitis treated with PTH (P + PTH), diabetes with 
periodontitis (DP), and diabetes with periodontitis treated with PTH (DP + PTH) groups. To induce type 1 diabetes, rats 
were injected with streptozotocin and periodontitis was induced bilaterally by applying ligatures to the mandibular 
first molars for 30 days. During the experimental period, the P + PTH and DP + PTH groups were subcutaneously 
injected with PTH (40 μg/kg) three times per week, whereas the C, P, and DP groups were injected with citrate buffer. 
To observe the mineralization of the alveolar bone, the DP and DP + PTH groups were injected with calcein on days 
10 and 27, and with alizarin red on day 20. Thirty days after ligation, histological findings and fluorescence labeling 
were analyzed in the furcations of the mandibular first molars. Sclerostin‑positive osteocytes were assessed by immu‑
nohistochemical analyses.
Results: The DP groups had smaller areas of alveolar bone than the other groups, and the DP + PTH group had a 
larger alveolar bone area than the DP group. The DP group had less osteoid formation than the C group, whereas the 
DP + PTH had greater osteoid formation than the DP group. Fluorescence labeling results revealed that the DP + PTH 
group had more mineral deposition on the alveolar bone than the DP group. The DP + PTH group exhibited lower 
percentage of sclerostin‑positive osteocytes in alveolar bone than the DP group.
Conclusions: Intermittent PTH administration diminishes alveolar bone loss and sclerostin expression in osteocytes, 
but increases osteoid formation and mineralization, suggesting that intermittent PTH administration attenuates 
diabetes‑aggravated alveolar bone loss by the induction of bone formation. PTH‑induced bone formation may be 
related to the regulation of osteocytic sclerostin expression in type 1 diabetic rats with periodontitis.
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Background
Parathyroid hormone (PTH), which is synthesized by 
the parathyroid glands, plays a role in the maintenance 
of blood calcium levels [1]. Preosteoblasts, osteoblasts, 
bone-lining cells, and osteocytes express PTH receptors 
[1]. PTH controls calcium homeostasis via the stimula-
tion of bone remodeling: This process is accomplished by 
direct effects on osteocytes and osteoblasts, and indirect 
effects on osteoclasts via its actions on osteocytes and 
osteoblasts [1]. Although PTH induces both bone resorp-
tion and bone formation, its effects are dependent on the 
frequency of PTH exposure [1]. Continuous and inter-
mittent PTH administration causes catabolic and ana-
bolic effects on bone, respectively [1–3]. PTH-mediated 
anabolic effects are related to the direct action of PTH 
on osteoblasts and osteocytes. In osteoblasts, intermit-
tent PTH administration promotes osteoblastogenesis, 
reduces osteoblast apoptosis, and reactivates quiescent 
bone-lining cells [1, 4, 5]. In an osteocyte cell line, PTH 
was shown to reduce sclerostin expression [6]. Sclerostin 
is mainly expressed by osteocytes, inhibiting Wnt bind-
ing to low-density lipoprotein receptor-related protein 
5/6 and subsequently decreasing bone formation [7–9]. 
The suppression of sclerostin expression induced by 
intermittent PTH administration has been demonstrated 
in the calvaria of the mice [10].
Periodontitis is an infectious disease induced by peri-
odontopathogens; it causes the loss of alveolar bone 
surrounding the roots of teeth and is a common cause 
of tooth loss [11]. Alveolar bone loss is induced by an 
acceleration of bone resorption and an attenuation of 
bone formation [11]. Placing ligatures around teeth 
induces periodontitis in rats, modeling alveolar bone 
loss [12–14]. Systemic intermittent PTH administra-
tion during the maintenance of ligature placement was 
shown to block alveolar bone loss [12]. The topical inter-
mittent application of PTH in gingiva after the removal 
of ligatures was shown to recover alveolar bone loss and 
increase osteoid formation on the alveolar bone surface 
[13]. These findings suggest an anabolic effect of inter-
mittent PTH administration on alveolar bone in rats with 
periodontitis.
Systemic diseases such as osteoporosis and diabetes 
are risk factors for periodontitis [15, 16]. In ovariecto-
mized rats with periodontitis, intermittent PTH admin-
istration was shown to reduce alveolar bone loss [17]. 
PTH-mediated anabolic effects on bone were observed 
in tibiae and alveolar bone of type 1 diabetic animals 
[18, 19]. However, the effects of PTH on alveolar bone 
formation and osteocytic sclerostin expression of rats 
with both periodontitis and type 1 diabetes have been 
not determined. Therefore, we investigated the anabolic 
effects of intermittent PTH administration in rats with 
streptozotocin (STZ)-induced type 1 diabetes accompa-
nied by periodontitis.
Methods
Animal experiments
After acclimation for 1 week, the F344 male rats (Japan 
SLC, Inc., Hamamatsu, Shizuoka, Japan) were divided 
into five groups: control (C, N = 10), periodontitis (P, 
N = 7), periodontitis treated with PTH (P + PTH, N = 7), 
diabetes with periodontitis (DP, N = 6), and diabetes with 
periodontitis treated with PTH (DP + PTH, N = 6). The 
experimental protocol is presented in Fig. 1a. After fast-
ing for 18  h, both diabetes groups were intravenously 
injected with STZ (50  mg/kg in 0.1  M citrate buffer, 
Sigma-Aldrich, St. Louis, MO, USA) and the non-diabe-
tes groups were injected with citrate buffer alone. On day 
7 after injection, blood was obtained from the tail vein, 
and glucose levels were measured using an Accu-Check 
active system (Roche, Mannheim, Germany) under fast-
ing conditions. Rats with a blood glucose level greater 
than 300 mg/dl were considered diabetes. Rats were then 
anesthetized with zoletil 50 (30  mg/kg; Virbac, Carros, 
France) and rompun (10  mg/kg; Bayer Korea, Ansan, 
Gyenoggi-do, Korea), and periodontitis was induced 
bilaterally by placing dental floss around the cervixes 
of the first mandibular molars. During 30 days after the 
induction of periodontitis, the P + PTH and DP + PTH 
groups were subcutaneously given PTH three times per 
week (40 μg/kg, Bachem, Torrance, CA, USA). PTH was 
administered 4 h before both the placement of the liga-
tures (day 0) and the time of sacrifice (day 30). During the 
experimental period, body weights and fasting glucose 
levels were measured to ensure maintenance of diabetes. 
The animal protocols were approved by the Institutional 
Animal Care and Use Committee of Yonsei University 
(Approval Number: 2015-0345).
Histological analysis of bone loss and bone formation
For histological analysis, the left mandibles and tibiae 
were fixed in 10% neutral-buffered formalin over-
night. The mandibles were decalcified in 10% ethylen-
ediaminetetraacetic acid (EDTA) for 2  months. Serial 
sagittal sections (4-μm-thick) were cut from paraffin-
embedded tissue blocks. The sections with clear dental 
pulp of the mesial and distal roots of the first molars 
were selected and stained with hematoxylin and eosin 
(H&E). Slides were scanned using a Aperio AT2 Digital 
Whole Slide scanner (Leica Microsystems Inc., Buffalo 
Grove, IL, USA) and analyzed using Aperio ImageScope 
software (version12.3.2.2013, Aperio Technologies Inc., 
Vista, CA, USA). The degree of alveolar bone loss in the 
furcation of the first molar was estimated by measur-
ing the percentage of the alveolar bone to the region 
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of interest (ROI) in the furcation. The ROI for alveolar 
bone loss extended 0.8 mm from the top of the furca-
tion. To determine bone formation, the osteoid region 
of the ROI in the furcation was measured, as previously 
described [20]. The ROI for bone formation extended 
0.5 mm from the remaining alveolar bone crest (ABC) 
in the furcation. The tibiae of the DP and DP + PTH 
groups were decalcified in 10% EDTA for 1 month. Tib-
ial sections appearing proximal epiphysial growth plate 
were selected and then stained with H&E.
Fluorescence calcein and alizarin red labeling
To analyze bone mineralization, calcein and alizarin 
red fluorochromes, which bind calcium in the miner-
alized areas of the bone, were injected into the DP and 
DP + PTH groups [21]. After placement of the liga-
tures around the teeth as described above, the DP and 
DP + PTH groups were given an intraperitoneal injection 
of calcein (10 mg/kg, Sigma-Aldrich, St Louis, MO, USA) 
on days 10 and 27, and alizarin red (20  mg/kg, Sigma-
Aldrich, St Louis, MO, USA) on day 20, respectively. 
On day 30 after placement of the ligatures, the right 
mandibles and tibiae were fixed in 10% neutral-buffered 
formalin and dehydrated in a graded series of etha-
nol solutions. The molar regions of the mandibles were 
embedded in methyl methacrylate-based resin and cut 
into 200-μm-thick sections (Struers, Germany). The sec-
tions were polished to obtain 50-μm slices using a hard 
tissue grinding system (EXAKT, Germany). Calcein and 
alizarin red labeling was observed in alveolar bone within 
the furcation of the first molars and trabecular bone 
under the epiphyseal growth plate of the tibiae by confo-
cal laser scanning microscopy (LSM 700, Zeiss, Göttin-
gen, Germany).
Immunohistochemical analyses of sclerostin expression
For sclerostin staining, sections of alveolar bone were 
deparaffinized and rehydrated through a series of graded 
ethanol solutions. To inhibit endogenous peroxidase 
activity, sections were quenched in 3%  H2O2 for 20 min 
and then treated with trypsin (Thermo Fisher Scientific, 
Waltham, MA, USA) for antigen retrieval. Immunohis-
tochemistry was carried out using universal kits (Vector 
Laboratories, Burlingame, CA, USA) according to the 
manufacturer’s instructions. Sections were preincubated 
with normal horse blocking solution for 20 min and then 
incubated overnight at 4 °C with goat anti-sclerostin anti-
body (1:300 dilution, R&D Systems, Minneapolis, MN, 
USA). Sections were developed using the 3,3′-diamin-
obenzidine chromogen and counterstained with methyl 
green. Slides were scanned using a Aperio AT2 Digital 
Whole Slide scanner (Leica Microsystems Inc., Buffalo 
Grove, IL, USA) and analyzed using Aperio ImageScope 
software (version12.3.2.2013, Aperio Technologies Inc., 
Vista, CA, USA). Numbers of sclerostin-positive osteo-
cytes were counted in the ROI, which extended 0.5 mm 
from the ABC in the furcations of the first molars, and 
are presented as the percentage of sclerostin-positive 
osteocytes per number of total osteocytes in the ROI.
Statistical analysis
All statistical analyses were performed using a statisti-
cal analysis program (SPSS, Chicago, IL, USA). One-way 
Fig. 1 Experimental protocol for intermittent PTH administration 
and changes in body weights and fasting glucose levels during the 
experimental period. Rats were divided into five groups: C, P, P + PTH, 
DP, and DP + PTH. a Experimental protocol: on 1 week after induction 
of diabetes by STZ, periodontitis was induced by placing bilateral 
ligatures around the mandibular first molars using dental floss. After 
placement of the ligatures, the DP and DP + PTH groups were given 
intraperitoneal injections of calcein (10 mg/kg) on days 10 and 27, 
and alizarin red (20 mg/kg) on day 20, respectively. During 30 days 
after the induction of periodontitis, the P + PTH and DP + PTH 
groups were subcutaneously administered PTH three times per week 
(40 μg/kg). On days 0 and 30, PTH was administered 4 h before both 
placement of the ligatures and the time of sacrifice, respectively. b 
Body weights in each group and c Fasting glucose levels in each 
group. Data are presented as the mean ± SE. *P < 0.05 compared with 
the C group
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analysis of variance followed by Scheffé’s method was 
used to determine significant differences. A value 
P < 0.05 was considered statistically significant. Data are 
expressed as the mean ± standard error (SE).
Results
Effects of PTH on body weights and fasting blood glucose 
levels
During the experimental period, C, P, and P + PTH 
groups showed a gradual increase in body weights, but 
the DP and DP + PTH groups maintained body weights 
(Fig.  1b). Fasting blood glucose levels of the C, P, and 
P + PTH groups were about 100  mg/dl and were main-
tained during the experimental period (Fig. 1c). However, 
fasting blood glucose levels of the DP and DP + PTH 
groups were greater than 300 mg/dl. There was no differ-
ence in body weights and fasting glucose levels between 
the DP and DP + PTH groups.
Effects of PTH on alveolar bone loss and bone formation
To estimate the effects of PTH on alveolar bone loss, the 
alveolar bone areas in the furcations of the first molars 
were measured (Fig.  2a). The alveolar bone areas of the 
P, P + PTH, DP, and DP + PTH groups were lower than 
the corresponding area in the C group. Interestingly, the 
DP + PTH group had more alveolar bone than did the DP 
group. To evaluate the effects of PTH on new bone for-
mation in alveolar bone, the osteoid region was estimated 
in the furcations of the first molars (Fig. 2b). While the 
osteoid area was larger in the P, P + PTH, and DP + PTH 
groups than in the C group, it was smaller in the DP 
group. Both the P and P + PTH groups had the larger 
osteoid areas than did the DP and DP + PTH groups. The 
DP + PTH group had the greater osteoid area than the 
DP group. Calcein- and alizarin red-labeled bone areas 
were larger in the DP + PTH group than in the DP group 
(Fig. 2c).
Fig. 2 The effects of intermittent PTH administration on alveolar bone loss and bone formation in the furcations. a Representative images of the 
alveolar bone area in each group (left panels; H&E stain; scale bar = 100 μm). Measurements of the alveolar bone area in each group (right panel). b 
Measurements of the osteoid area in each group. c Representative images of labeled alveolar bone surfaces by calcein and alizarin red fluorescence 
in the DP and DP + PTH groups (scale bar = 100 μm). Data are presented as the mean ± SE. *P < 0.05 compared with the C group. #P < 0.05. AB 
alveolar bone; BM bone marrow, PDL periodontal ligament
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Effects of PTH on tibial bone loss and bone formation
To confirm the anabolic effects of PTH on other bone, 
trabecular bone in the tibiae was observed by H&E 
staining and fluorescence labeling. The DP + PTH 
group showed more trabecular bone than the DP 
group by H&E staining (Fig.  3a), and the DP + PTH 
group showed a larger calcein- and alizarin red-labeled 
area in trabecular bone than the DP group (Fig. 3b).
Effects of PTH on sclerostin expression in alveolar bone
To estimate the effects of PTH on sclerostin expression 
in alveolar bone, sclerostin-positive osteocytes were 
counted in the furcations of the first molars (Fig.  4). 
The percentage of sclerostin-positive osteocytes was 
greater in the DP group than in the other groups. 
While that of DP + PTH group was lower than in the 
DP group, it was higher than in the P + PTH group.
Discussion
The frequency of PTH administration required to ele-
vate PTH levels intermittently varies from daily to a few 
times per week. Daily PTH administration increases 
osteoblast number and bone formation in rat tibiae, 
whereas continuous PTH infusion via an osmotic pump 
results in systemic effects, including bone resorption 
and bone marrow fibrosis, suggesting that intermittent 
PTH administration is required for the anabolic effects 
of this hormone [2]. In both rats with periodontitis and 
ovariectomized rats with periodontitis, anabolic effects 
on alveolar bone were induced by PTH administration 
three times per week for 1 month [12, 17]. Based on the 
data generated by these two groups, we administered 
PTH three times per week for 1 month in type 1 diabetic 
rats with periodontitis. PTH administration in periodon-
titis condition did not result in a significant increase in 
the area of the alveolar bone compared to the P group, 
but PTH administration in periodontitis with diabetes 
condition elicited its improvement compared to the DP 
Fig. 3 The effects of intermittent PTH administration in tibiae. a Representative images of trabecular bone in tibiae of the DP and DP + PTH groups 
(H&E stain; scale bar = 100 μm). b Representative images of labeled trabecular bone surfaces by calcein and alizarin red fluorescence in the DP and 
DP + PTH groups (scale bar = 100 μm)
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group. These findings suggest that intermittent PTH 
administration may attenuate diabetes-aggravated alveo-
lar bone loss in type 1 diabetic rats with periodontitis. A 
study of PTH-treated ovariectomized rats with periodon-
titis (three times per week) showed recovery of alveolar 
bone loss to levels of normal rats [17]; these results are 
inconsistent to our findings, where alveolar bone loss in 
the DP + PTH group did not recover to levels of the C 
group. The characteristics of systemic diseases related to 
bone loss might contribute to differences in the level of 
protection against alveolar bone loss. Additionally, daily 
PTH administration in mice with type 1 diabetes caused 
an elevation of trabecular bone density in the tibiae to 
levels of normal mice [18]. To improve rates of bone pro-
tection in cases of type 1 diabetes with periodontitis after 
PTH administration, the optimal therapeutic strategy 
considering bone type in PTH administration might be 
considered.
Bone loss was determined by the level of bone forma-
tion. As in study of rats with periodontitis treated inter-
mittently with PTH [13], we also found greater osteoid 
area in alveolar bone of the DP + PTH group compared 
to the DP group. In addition, mineral deposition in alve-
olar bone was greater in the DP + PTH group than in 
the DP group, suggesting an anabolic effect of PTH on 
alveolar bone in type 1 diabetic rats with periodontitis. 
In long bones of type 1 diabetic mice, daily PTH admin-
istration increased trabecular bone density accompanied 
by increased mineral apposition and an increase in the 
number of osteoblasts lining the bone surface [18]. In our 
study, tibiae of the DP + PTH group had an increase in 
trabecular bone and mineral deposition compared with 
the DP group. These findings suggest that PTH has simi-
lar anabolic effects on trabecular bone (e.g., the tibia) as 
on alveolar bone in type 1 diabetes.
In previous studies of rats with periodontitis, treatment 
with sclerostin antibodies was found to induce an ana-
bolic response during alveolar bone healing by increasing 
bone formation [15, 22]. Sclerostin in osteocytes is pro-
posed to be a target gene of PTH in vivo [1, 6, 10]. Daily 
PTH administration has been shown to increase osteo-
blast activity in normal mice, with no effects in mice lack-
ing PTH receptors in osteocytes [23]. In addition, a single 
PTH administration was shown to decrease the number 
of sclerostin-positive osteocytes in vertebral trabecular 
bone in normal mice but failed to suppress the number 
of sclerostin-positive osteocytes in mice lacking PTH 
receptors [23]. These results suggest that osteocytes play 
a significant role in the anabolic effects of intermittent 
PTH administration. A single PTH administration was 
found to induce a transient decline in sclerostin mRNA 
levels in mice vertebrae and rat femurs [6, 10]. Daily PTH 
administration for 2 months was found to induce a steady 
decline in sclerostin mRNA levels in femurs of estrogen-
deprived rats, suggesting that inhibition of sclerostin is 
sustained by long-term intermittent PTH administration 
[10]. In this study, more sclerostin-positive osteocytes 
were observed in the DP group compared to the C group. 
There was no significant difference in sclerostin expres-
sion in the P + PTH group compared to the P group, but 
sclerostin expression was lower in the DP + PTH group 
compared to the DP group. Our results suggest that 
PTH may have an inhibitory effect on the induction of 
sclerostin expression in alveolar bone by diabetes simi-
lar to results seen in a study of estrogen-deprived rats 
treated with PTH [10]. Taken together, decreased scle-
rostin expression in osteocytes after intermittent PTH 
administration appears to be involved in the increase 
in bone formation observed in type 1 diabetic rats with 
periodontitis.
Conclusions
In summary, these results indicate that intermittent PTH 
administration increases osteoid formation and minerali-
zation, and diminishes alveolar bone loss and sclerostin 
expression in osteocytes of type 1 diabetic rats with peri-
odontitis. Therefore, intermittent PTH administration 
Fig. 4 The effects of intermittent PTH administration on 
osteocytic sclerostin expression in alveolar bone. Representative 
images of sclerostin‑positive osteocytes in the DP and DP + PTH 
groups. White and red arrowheads indicate representative 
sclerostin‑negative and ‑positive osteocytes, respectively (upper 
panels; immunohistochemistry; scale bar = 100 μm). Percentage of 
sclerostin‑positive osteocytes in each group (lower panel). Data are 
presented as the mean ± SE. *P < 0.05 compared with the C group. 
#P < 0.05
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may improve bone formation and attenuate diabetes-
aggravated bone loss by decreasing sclerostin expression 
in osteocytes of type 1 diabetic rats with periodontitis.
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